RecruitingNot ApplicableNCT04823923

Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer

Study of the Impact of the Stage of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors (ITK) in Patients Treated for Metastatic Kidney Cancer

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle

Enrollment

60 participants

Start Date

Dec 6, 2021

Study Type

INTERVENTIONAL

Conditions

Kidney Neoplasm

Summary

The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how chronic kidney disease affects the blood levels of targeted cancer drugs (kinase inhibitors like pazopanib or cabozantinib) used to treat metastatic kidney cancer. Understanding this could help doctors adjust doses more accurately for patients with both cancer and kidney problems. **You may be eligible if...** - You are 18 years or older - You have metastatic clear cell kidney cancer - You are currently being treated with pazopanib or cabozantinib - You may or may not have chronic kidney disease **You may NOT be eligible if...** - You are not being treated with one of the two specified drugs - You do not have a diagnosis of metastatic clear cell kidney cancer - You are unable to comply with scheduled blood draws and visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERblood sampling for ITK dosage

Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)